IND-Enabling Studies: Timeline, Cost, and What You Need

The question I get most often from biotech CSOs: "How long does it take and how much does it cost to get from candidate selection to IND filing?" The honest answer is 12-18 months and $2-6M for a small molecule, and 15-24 months and $4-10M for a biologic. The unhelpful answer is "it depends." Both answers are correct. I'll try to make the second one actually useful.

The IND-enabling nonclinical package is the set of studies required by ICH M3(R2) to support first-in-human dosing. Get the package right and your IND has a smooth path through FDA's 30-day review. Get it wrong and you're looking at a clinical hold — 6-12 months of delay, $2-4M in burned runway, and a conversation with your board that nobody wants to have.

I'm going to walk through the package study by study — costs, timelines, sequencing — because the scheduling decisions matter almost as much as the scientific ones. A well-designed nonclinical program run in the wrong order adds 6 months. I've seen it happen.

The required studies

Per ICH M3(R2), a standard Phase 1 IND for a small molecule requires:

Additional studies that may be required depending on the drug and clinical population:

Costs by study type

These are 2025-2026 estimates based on conversations with CROs and biotech companies. Prices vary by CRO, region, and specific study design. North American CROs are generally 20-40% more expensive than European or Asian CROs, but geographic proximity to the sponsor and FDA familiarity have value.

Toxicology

Total tox cost: $1.0-1.8M (including dose range-finding)

The dose range-finding studies aren't strictly required by M3(R2), but skipping them is a false economy. Running your $500K GLP dog study without knowing the approximate MTD means you risk selecting dose levels that are either too low (inadequate exposure margins, FDA questions) or too high (excessive toxicity, animals lost, study may need to be repeated). The $150K DRF study protects the $500K pivotal study.

Safety pharmacology

Total safety pharm cost: $270-530K

If you integrate cardiovascular endpoints into the dog repeat-dose tox study (telemetered beagles), you can save $100-150K and 2-3 months. But discuss this with your CRO and regulatory adviser — the integrated approach must be specifically designed for safety pharmacology assessment, not just incidental data collection during tox.

Genotoxicity

Total genotox cost: $75-135K

Genotoxicity is the cheapest component of the package and the fastest to execute. It's also the one that catches people most frequently by surprise — a positive Ames test or in vitro chromosomal aberration result triggers follow-up studies that can add 2-3 months to your timeline. Run the Ames test early. If you get a positive result, you want to know that with enough runway to plan the follow-up strategy.

Pharmacokinetics

Total PK cost: $160-320K

PK studies are typically non-GLP (the data is accepted without GLP status for most programs), but the bioanalytical method validation should follow FDA's Bioanalytical Method Validation guidance. The validated method will be used for TK analysis in your GLP tox studies, so it needs to be ready before those studies start.

Reproductive toxicity (if needed)

If enrolling women of childbearing potential in Phase 1: Add $450-750K and 4-6 months.

Most first-time sponsors enroll only male subjects in Phase 1 to defer reproductive tox studies to later development, per ICH M3(R2). This is a legitimate strategy. But if your Phase 1 protocol includes women of childbearing potential — common in oncology trials in patients — you need embryo-fetal development data before the first female subject is dosed.

Total cost summary

These ranges include CRO costs for study conduct, not internal headcount. Add $500K-$1M/year for the internal team (head of preclinical, regulatory affairs, CMC — minimum 2-3 FTEs during IND-enabling).

The critical path

Most timeline problems come from poor sequencing. Some studies must finish before others can start. Some run in parallel. Getting this wrong is expensive.

Months 1-3: Preparation

• Bioanalytical method development and validation — must be ready before GLP tox
• In vitro ADME screening — metabolic stability, CYP inhibition, protein binding
• Test article (drug substance) manufacture — you need enough GMP-quality material for all studies
• Dose formulation development — stability and homogeneity data needed before GLP studies
• Ames test — start early, get the genotox result before committing fully

Months 2-5: Dose range-finding

• 14-day rat DRF — select dose levels for pivotal 28-day study
• 14-day dog DRF — select dose levels for pivotal 28-day study
• Single-dose PK — rat and dog, to inform tox study dose selection

Months 4-10: Pivotal GLP studies (parallel)

• 28-day rat repeat-dose tox (GLP) — 3-5 months in-life + reporting
• 28-day dog repeat-dose tox (GLP) — 4-7 months in-life + reporting
• Safety pharmacology core battery (GLP) — 4-6 months
• In vitro genotoxicity — Ames + chromosomal aberration
• In vivo genotoxicity — micronucleus study

Months 8-12: Reporting and IND assembly

• Study reports from CROs — GLP study reports take 6-10 weeks after study completion
• Module 2.4 Nonclinical Overview — integrated narrative (writing guide here)
• Module 2.6 Written and Tabulated Summaries — discipline-by-discipline summaries
• Dose justification — NOAEL to HED calculation
• IND assembly — eCTD formatting, cross-referencing, QC

The critical path item

In most programs, the dog repeat-dose toxicity study is the rate-limiting study. It takes the longest, has the most complex logistics (surgical telemetry implantation, limited CRO slots for beagle studies), and the final report takes the longest to produce (histopathology peer review for dog studies is time-intensive).

Schedule the dog study first. Everything else can work around it.

CRO selection

A few things I've learned from companies that went through this:

Don't choose the cheapest CRO. The cheapest CRO is cheap for a reason. Sometimes it's efficiency. Sometimes it's cutting corners on quality systems. A GLP deviation that requires repeating a $500K study is not a discount.

Verify GLP compliance. Ask for the CRO's most recent FDA inspection outcome. Check the FDA's GLP inspection database. If the CRO received a Warning Letter or had significant 483 observations, understand what was found and whether it's been corrected.

Visit the facility. Yes, physically. Before you place a $1M+ contract. Look at the animal rooms. Look at the analytical lab. Talk to the study directors who will run your studies. Ask about their workload — an overloaded study director is a risk factor for errors.

Lock in your slots early. CRO capacity for GLP tox studies is finite, especially for large-animal (dog, NHP) studies. 3-6 months of lead time is typical. If you're planning to start your GLP dog study in January, place the contract by July. Waiting until October means your study doesn't start until April, and your IND slides 3 months.

Negotiate report timelines. The in-life phase of a tox study is only part of the timeline. The draft report takes 6-10 weeks after study completion. The final report takes another 2-4 weeks after sponsor review. Build these timelines into your project plan. Some CROs will commit to expedited reporting for an additional fee — worth considering if you're timeline-constrained.

What goes wrong

Test article supply runs out mid-study. You manufactured 500g of drug substance. Your rat study uses 200g. Your dog study uses 150g. Your safety pharmacology studies use 100g. Your genotoxicity studies use 30g. That's 480g, leaving 20g for reserve samples and dose formulation verification. Then you discover you need additional formulation stability work and you're short. Manufacture more than you think you need. Add a 30-50% buffer.

The DRF results surprise you. Your dose range-finding study shows unexpected toxicity at doses lower than expected, or unexpected lack of exposure at the planned doses. Now your pivotal study design needs to change. This is why DRF studies exist — they're the insurance policy for the pivotal studies. Don't skip them.

GLP report delays. The CRO's pathologist is backed up. The QA review takes longer than expected. Your study report arrives 4 weeks later than planned, and your IND filing date slips. I've seen this happen on almost every program I've been close to. Build buffer into your timeline. If the CRO says "8 weeks from study completion to draft report," plan for 10.

Cross-study inconsistencies. Different CROs running different studies, using different analytical methods for the same compound. Your TK levels in the rat study can't be compared to your TK levels in the dog study because the bioanalytical methods have different lower limits of quantification. Use the same bioanalytical method (validated once) across all studies.

Planning backward

Start with your target IND filing date and work backward. This is the single piece of project management advice that I think actually changes outcomes in preclinical development.

IND filing: Month 18. Module 2 writing: Months 15-18. GLP study reports available: Month 14. GLP studies start: Month 6. DRF studies start: Month 3. Bioanalytical validation: Month 1. Test article manufacturing: Month 0.

If any milestone can't be met, your filing date adjusts. Not your ambitions — the filing date. A 28-day dog tox study takes 28 days of dosing plus 14 days of recovery plus 6-8 weeks of pathology and reporting. You can't compress biology.

One thing I didn't expect when I started looking at this space: the biggest source of timeline variance isn't the studies themselves. It's the reporting. CRO pathologists get backed up. QA review queues extend. Your draft report arrives three weeks late and suddenly your regulatory writer has half the time to produce Module 2.4. I've talked to companies that planned every study meticulously and then lost two months to report delays because they built the Gantt chart around in-life dates and forgot that the report isn't the study — it's a second project that starts when the first one ends.

The other thing nobody tells you about IND-enabling timelines: they compress non-linearly as you approach filing. The first six months feel spacious. Months 12-15 feel like the walls are closing in. By month 16, people are working weekends. This isn't a scheduling failure — it's a feature of the process, because late-arriving data (the final histopath read, the QA statement, the last TK data point) feeds into documents that can't be written until those data exist. The end of an IND-enabling program is inherently a bottleneck, and the only thing you can do about it is start earlier than you think you need to.

---

Related reading:

• FDA IND Submission Checklist 2026 — complete requirements by CTD module
• GLP Compliance Checklist for Preclinical Studies — 21 CFR Part 58 requirements
• 5 Most Common IND Deficiencies — what to check before filing
• How to Write CTD Module 2.4 Nonclinical Overview — the narrative that ties it together

FAQ

How long do IND-enabling studies take from start to finish?

For a standard small molecule Phase 1 program with male-only subjects, the realistic timeline from candidate selection to IND filing is 12-18 months. Biologics programs run 15-24 months. The single biggest driver of timeline length is the dog repeat-dose toxicity study — 28 days of dosing, 14 days of recovery, 6-10 weeks for the draft study report, another 2-4 weeks for the final. That's 5-7 months for one study. Before that study starts, you need bioanalytical method validation (6-10 weeks), dose range-finding (2-4 months), and test article manufacture. After it ends, you write Module 2 summaries and assemble the IND. The most common source of timeline slip isn't the biology — it's CRO report delays. Study directors get backed up, histopathology peer review queues extend, and a 10-week report estimate turns into 14 weeks. Build buffer: if your CRO says 8 weeks, plan for 11.

How much do IND-enabling studies cost?

Total CRO costs for a standard small molecule Phase 1 IND-enabling program run $1.5-2.8M for a males-only program and $2.0-3.5M if you need to include women of childbearing potential in Phase 1. The biggest line items are repeat-dose toxicology: a 28-day GLP rat tox study costs $300-500K, a 28-day GLP dog tox study costs $500-900K. Safety pharmacology adds $270-530K. Genotoxicity ($75-135K) and PK ($160-320K) are smaller. If you need reproductive toxicology — embryo-fetal development in rat and rabbit — add $450-750K and 4-6 months. These figures are 2025-2026 estimates for North American CROs; European and Asian CROs are typically 20-40% cheaper. Add $500K-$1M/year for internal headcount (preclinical lead, RA, CMC). Total all-in spend from candidate selection to IND filing: $2.5-5M for most small molecule programs.

What is the minimum nonclinical package for a Phase 1 IND?

Per ICH M3(R2), the minimum package for a Phase 1 single ascending dose study in male healthy volunteers includes: repeat-dose toxicity in 2 species with duration matched to clinical trial length (ICH M3(R2) Table 1), safety pharmacology core battery covering cardiovascular, CNS, and respiratory systems per ICH S7A plus in vitro hERG per ICH S7B, a 3-test genotoxicity battery per ICH S2(R1) (Ames test, in vitro chromosomal damage assay, in vivo micronucleus), and pharmacokinetic characterization in both species. Single-dose toxicity can be integrated into the repeat-dose studies. Local tolerance data is required for novel routes of administration. All pivotal studies must be conducted under GLP per 21 CFR Part 58, with written justification for any exceptions. There's no minimum for reproductive toxicity for males-only Phase 1, but embryo-fetal development data in 2 species is required before enrolling women of childbearing potential.

Can I run IND-enabling studies in parallel?

Yes — and parallel execution is essential to hitting a 12-15 month timeline. The studies that must run sequentially are: bioanalytical method validation must complete before GLP tox starts (the validated method is used for toxicokinetic analysis), and dose range-finding studies must complete before the pivotal GLP studies begin (you need MTD data to set dose levels). Within the pivotal phase, everything else runs in parallel: rat repeat-dose tox, dog repeat-dose tox, safety pharmacology core battery, and the genotoxicity battery can all run simultaneously across multiple CROs. Module 2 writing can start in parallel with the last studies using draft data, so long as final data is available before the IND QC review. The critical path item in most programs is the dog repeat-dose tox — it takes the longest and has the most limited CRO capacity. Schedule it first, and run everything else around it.

What CRO should I use for IND-enabling studies?

There's no single right answer, but there are specific things to check. Start by verifying FDA GLP inspection history — search the FDA bioresearch monitoring compliance database and look for Warning Letters or significant 483 observations in the past 3 years. Then visit the facility before signing a $1M+ contract: walk the animal rooms, meet the study directors who will run your actual studies, ask about their current workload and slot availability. Verify that the CRO's bioanalytical capabilities match your compound's analytical requirements. Large CROs like Charles River, Covance (Labcorp Drug Development), Envigo/Inotiv, and Pacific Biosciences offer end-to-end packages; smaller specialty CROs may offer better timelines for specific study types. Don't choose on price alone — a GLP deviation that forces you to repeat a $500K dog study is not a discount. Lock in slots 3-6 months before your target study start date.

Do I need both rat and dog studies for a small molecule IND?

Yes, for a standard small molecule Phase 1 IND. ICH M3(R2) requires repeat-dose toxicity in one rodent species (typically rat) and one non-rodent species (typically dog). The non-rodent requirement exists because some toxicities are species-specific and a second unrelated species provides additional safety information. Dogs are standard for small molecules; non-human primates are used when the compound has species-specific pharmacology that limits rat and dog relevance. For biologics, ICH S6(R1) takes a different approach — you're required to test in pharmacologically relevant species, and sometimes that's only one species (often cynomolgus monkey for monoclonal antibodies). If you're developing a small molecule and considering skipping the dog study, you'll need a strong scientific justification. The most common acceptable reason is species-specific metabolism that makes dog data scientifically uninformative — and you'll need comparative in vitro metabolism data to support that argument.

When should I start IND-enabling studies relative to my IND filing date?

Work backward from your target IND filing date. IND filing: Month 18. Module 2 writing: Months 15-18. Final GLP study reports in hand: Month 14. Pivotal GLP studies start: Month 5-6. Dose range-finding studies start: Month 3. Bioanalytical method validation starts: Month 1. Test article manufacture: Month 0. This means if you want to file an IND in January 2027, your bioanalytical validation should start in July 2025 and your dog tox study should be under contract by October 2025. The number I'd emphasize most: lock in CRO contracts 3-6 months before your planned study start date. GLP tox CROs — especially for large-animal studies — have limited slot availability. Waiting until 6 weeks before your planned start date to place the contract is one of the most common causes of 3-6 month timeline slippage, and it's entirely preventable.